Sign Up

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

JUPITER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Craig-Hallum Capital Group LLC is acting as the sole managing underwriter for the offering.

Dyadic intends to use the net proceeds from the proposed offering for working capital and general corporate purposes, such as product development, sales and marketing.

The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273829) initially filed with the Securities and Exchange Commission ("SEC") on August 9, 2023 and declared effective by the SEC on August 25, 2023. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained by visiting the SEC's website at www.sec.gov or by contacting Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 323 N. Washington Ave, Suite 300, Minneapolis, MN 55401, by telephone at (612) 334-6300 or by email at The final terms of the offering will be disclosed in a final prospectus supplement to be filed with ...